NCT01031225

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: Synta Pharmaceuticals Corp. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	STA 9090	STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval

Timeline

• Start date: 2009-11-01
• Primary completion: 2013-07-01
• Completion: 2014-02-01
• First posted: 2009-12-14
• Last updated: 2014-09-19

Locations

21 sites across 1 country: United States